CY1122835T1 - Συνδυαστικη θεραπεια - Google Patents
Συνδυαστικη θεραπειαInfo
- Publication number
- CY1122835T1 CY1122835T1 CY20201100245T CY201100245T CY1122835T1 CY 1122835 T1 CY1122835 T1 CY 1122835T1 CY 20201100245 T CY20201100245 T CY 20201100245T CY 201100245 T CY201100245 T CY 201100245T CY 1122835 T1 CY1122835 T1 CY 1122835T1
- Authority
- CY
- Cyprus
- Prior art keywords
- alaninyl
- phosphate
- combined therapy
- cancer
- lipoplatin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Αυτή η εφεύρεση σχετίζεται με έναν συνδυασμό της [φαινυλο-βενζοξυ-L-αλανινυλο)]-φωσφορικής γεμσιταβίνης (χημική ονομασία: 2'-δεοξυ-2', 2'-διφθορο-D-κυτιδίνη-5'-Ο-L-αλανινυλο)]φωσφορική (ΝUC-1031) και ενός αντικαρκινικού παράγοντα με βάση την πλατίνα που επιλέγεται από σισπλατίνη, πικοπλατίνη, λιποπλατίνη και τριπλατίνη. Οι συνδυασμοί είναι χρήσιμοι στη θεραπεία του καρκίνου και ειδικότερα του καρκίνου της χοληφόρου οδού και της ουροδόχου κύστης.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2015/054158 WO2017109444A1 (en) | 2015-12-23 | 2015-12-23 | Combination therapy |
| GBGB1609770.1A GB201609770D0 (en) | 2016-06-03 | 2016-06-03 | Combination therapy |
| PCT/GB2016/054018 WO2017109486A1 (en) | 2015-12-23 | 2016-12-21 | Combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122835T1 true CY1122835T1 (el) | 2021-05-05 |
Family
ID=57681677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100245T CY1122835T1 (el) | 2015-12-23 | 2020-03-17 | Συνδυαστικη θεραπεια |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20190022117A1 (el) |
| EP (2) | EP3738595A1 (el) |
| JP (1) | JP6898329B2 (el) |
| KR (1) | KR20180096698A (el) |
| CN (1) | CN108697725A (el) |
| AU (1) | AU2016375861B2 (el) |
| CA (1) | CA3008749C (el) |
| CY (1) | CY1122835T1 (el) |
| DK (1) | DK3393478T3 (el) |
| EA (1) | EA037459B1 (el) |
| ES (1) | ES2778933T3 (el) |
| HK (1) | HK1255110A1 (el) |
| HR (1) | HRP20200423T1 (el) |
| HU (1) | HUE050290T2 (el) |
| IL (1) | IL260076A (el) |
| LT (1) | LT3393478T (el) |
| MA (1) | MA51576A (el) |
| MD (1) | MD3393478T2 (el) |
| ME (1) | ME03677B (el) |
| MX (1) | MX2018007772A (el) |
| MY (1) | MY194629A (el) |
| PH (1) | PH12018501339A1 (el) |
| PL (1) | PL3393478T3 (el) |
| PT (1) | PT3393478T (el) |
| RS (1) | RS60211B1 (el) |
| SG (1) | SG11201805184TA (el) |
| SI (1) | SI3393478T1 (el) |
| WO (1) | WO2017109486A1 (el) |
| ZA (1) | ZA201804155B (el) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3150616T (pt) | 2012-11-16 | 2017-06-09 | Univ College Cardiff Consultants Ltd | Mistura de rp/sp gencitabina-[fenil-(benziloxi-l-alaninil)]-fosfato |
| WO2015198058A1 (en) | 2014-06-25 | 2015-12-30 | Nucana Biomed Limited | Gemcitabine prodrugs |
| ES2655820T3 (es) | 2014-06-25 | 2018-02-21 | NuCana plc | Formulación que comprende un profármaco de gemcitabina |
| GB201417644D0 (en) | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
| WO2017060661A1 (en) | 2015-10-05 | 2017-04-13 | Nucana Biomed Limited | Combination therapy |
| WO2017098252A1 (en) | 2015-12-11 | 2017-06-15 | Nucana Biomed Limited | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 |
| GB201522771D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Crystalline form of a phosphate derivative |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| AU2012387679A1 (en) * | 2012-08-13 | 2014-10-23 | Regulon, Inc. | Methods for treatment of cancer using Lipoplatin |
| BR112015010941A2 (pt) * | 2012-11-13 | 2017-07-11 | Boyen Therapeutics Inc | pró-fármacos de gemcitabina e suas utilizações |
| KR20180021697A (ko) * | 2015-05-14 | 2018-03-05 | 뉴카나 피엘씨 | 암 치료 |
| WO2017060661A1 (en) * | 2015-10-05 | 2017-04-13 | Nucana Biomed Limited | Combination therapy |
-
2016
- 2016-12-21 RS RS20200297A patent/RS60211B1/sr unknown
- 2016-12-21 PL PL16820005T patent/PL3393478T3/pl unknown
- 2016-12-21 JP JP2018532746A patent/JP6898329B2/ja active Active
- 2016-12-21 WO PCT/GB2016/054018 patent/WO2017109486A1/en active Application Filing
- 2016-12-21 MX MX2018007772A patent/MX2018007772A/es unknown
- 2016-12-21 ES ES16820005T patent/ES2778933T3/es active Active
- 2016-12-21 ME MEP-2020-56A patent/ME03677B/me unknown
- 2016-12-21 MA MA051576A patent/MA51576A/fr unknown
- 2016-12-21 HU HUE16820005A patent/HUE050290T2/hu unknown
- 2016-12-21 SI SI201630680T patent/SI3393478T1/sl unknown
- 2016-12-21 AU AU2016375861A patent/AU2016375861B2/en not_active Ceased
- 2016-12-21 MY MYPI2018001015A patent/MY194629A/en unknown
- 2016-12-21 US US16/065,498 patent/US20190022117A1/en not_active Abandoned
- 2016-12-21 CN CN201680082464.9A patent/CN108697725A/zh active Pending
- 2016-12-21 EA EA201891473A patent/EA037459B1/ru unknown
- 2016-12-21 EP EP20160070.7A patent/EP3738595A1/en not_active Withdrawn
- 2016-12-21 LT LTEP16820005.3T patent/LT3393478T/lt unknown
- 2016-12-21 KR KR1020187020533A patent/KR20180096698A/ko not_active Application Discontinuation
- 2016-12-21 MD MDE20181039T patent/MD3393478T2/ro not_active IP Right Cessation
- 2016-12-21 SG SG11201805184TA patent/SG11201805184TA/en unknown
- 2016-12-21 EP EP16820005.3A patent/EP3393478B1/en active Active
- 2016-12-21 DK DK16820005.3T patent/DK3393478T3/da active
- 2016-12-21 CA CA3008749A patent/CA3008749C/en active Active
- 2016-12-21 PT PT168200053T patent/PT3393478T/pt unknown
-
2018
- 2018-06-17 IL IL260076A patent/IL260076A/en unknown
- 2018-06-21 PH PH12018501339A patent/PH12018501339A1/en unknown
- 2018-06-21 ZA ZA2018/04155A patent/ZA201804155B/en unknown
- 2018-11-08 HK HK18114265.9A patent/HK1255110A1/zh not_active IP Right Cessation
-
2020
- 2020-03-16 HR HRP20200423TT patent/HRP20200423T1/hr unknown
- 2020-03-17 CY CY20201100245T patent/CY1122835T1/el unknown
-
2022
- 2022-06-21 US US17/845,878 patent/US20230149436A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122835T1 (el) | Συνδυαστικη θεραπεια | |
| PH12018500691A1 (en) | Combination therapy | |
| CY1120582T1 (el) | Φαρμακευτικες συνθεσεις για την αγωγη παθησεων μεσολαβουμενων απο ρυθμιστη διαμεμβρανικης αγωγιμοτητας κυστικης ινωσης | |
| CY1120536T1 (el) | Μεθοδος και συνθεσεις για τη θεραπευτικη αγωγη του καρκινου | |
| ECSP20021323A (es) | Proteínas de unión condicionalmente activadas restringidas | |
| CY1122984T1 (el) | Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους | |
| CY1118216T1 (el) | Μεθοδοι αγωγης καρκινου | |
| MA44110B1 (fr) | Polythérapie | |
| CY1120318T1 (el) | Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων | |
| CY1120048T1 (el) | Συνθεσεις για την αγωγη γαστρεντερικης φλεγμονης | |
| CY1118695T1 (el) | Αναστολεις απομεθυλασων ιστονων | |
| EA201890272A1 (ru) | Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака | |
| CY1121465T1 (el) | Μεθοδοι και συνθεσεις για τη θεραπεια της φλεγμονωδους νοσου του εντερου | |
| MA45809A (fr) | Promédicaments de pth | |
| CY1124331T1 (el) | Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης | |
| BR112017015499A2 (pt) | ?composição, e, métodos para tratar uma condição associada com células hiperprolifereantes, e para destruir uma célula microbiana? | |
| CY1123043T1 (el) | Συνδυαστικες θεραπειες για την αγωγη ανθεκτικων στη χημειοθεραπεια καρκινων | |
| CY1122968T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο | |
| CY1124529T1 (el) | Ενωσεις λευκοχρυσου λειτουργικοποιημενες με μονομηλεινιμιδιο για θεραπεια καρκινου | |
| TR201911042T4 (tr) | Sinovit Tedavisinde veya Önlenmesinde Kullanım İçin Anti-İnflamatuar Fitobesinler. | |
| CY1118081T1 (el) | Παρασκευασματα συνδυασμου με εξωσωματα και κορτικοστεροειδες | |
| CY1122998T1 (el) | Μεθοδοι και συνθεσεις για την αντιμετωπιση της καταθλιψης χρησιμοποιωντας κυκλοβενζαπρινη | |
| MX2010009782A (es) | Tratamientos antitumorales mejorados. | |
| WO2015073896A3 (en) | Biomarkers for psma targeted therapy for prostate cancer | |
| CY1122357T1 (el) | Αντικαρκινικος συνδυασμος που περιλαμβανει καμπαζιταξελη και σισπλατινη |